The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 101–200 of 1,003
DeWitt, J. C., Shnyra, A., Badr, M. Z., Loveless, S. E., Hoban, D., Frame, S. R., Cunard, R., Anderson, S. E., Meade, B. J., Peden-Adams, M. M., et al. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440802209804 · Cited by 266
“To investigate the immunoregulatory effects of exposure to PPARα ligands, two relatively selective PPARα ligands have been examined (Maloney and Waxman, 1999; Willson et al., 2000).”
Background4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ
Coward, P., Lee, D., Hull, M. V., & Lehmann, J. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151244398 · Cited by 265
Panigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., & Kieran, M. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711281105 · Cited by 269
“Bezafibrate is a pan-PPAR agonist that activates all three nuclear receptors, PPAR , PPAR , and PPAR (22).”
BackgroundInfluentialHeneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269
“the submicromolar range ( Willson et al., 2000 ), and there are as yet no data to suggest binding to other proteins, troglitazone was reported to block iNOS expression in microglial cells without activating a PPAR-responsive reporter gene (Petrova et al., 1999).”
BackgroundInfluentialDeplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J.-C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06264.2003 · Cited by 219
“However, PPARs had not been discovered when this experiment was performed, but it has now been demonstrated that bezafibrate activates both PPAR- and PPAR- (Willson et al., 2000; Inoue et al., 2001).”
BackgroundSundararajan, S., Gamboa, J. L., Victor, N. A., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255
Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones
Bruno, G., Costantino, L., Curinga, C., Maccari, R., Monforte, F., Nicolò, F., Ottanà, R., & Vigorita, M. G. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00366-2 · Cited by 252
International Union of Pharmacology. LXVI. Orphan Nuclear Receptors
Benoit, G., Cooney, A., Giguere, V., Ingraham, H., Lazar, M., Muscat, G., Perlmann, T., Renaud, J.-P., Schwabe, J., Sladek, F., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.10 · Cited by 236
“Two prime examples are the RXRs and PPARs, which were discovered as orphan NRs, but which are now clearly considered to be liganded receptors, although the precise identity of their physiological, endogenous ligands is somewhat controversial (Gottlicher et al., 1992; Heyman et al., 1992; Kitareewan et al., 1996; Lemot…”
BackgroundStructural studies on nuclear receptors
Renaud, J. P., & Moras*, D. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000656 · Cited by 238
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246
“The bezafibrate lessons: feasibility of dual and pan-PPAR co-agonism in a clinical setting The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan – (alpha, beta/delta, gamma) PPAR activator [26-33].”
BackgroundWestergaard, M., Henningsen, J., Kratchmarova, I., Kristiansen, K., Svendsen, M. L., Johansen, C., Jensen, U. B., Schrøder, H. D., Berge, R. K., Iversen, L., et al. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01329.x · Cited by 241
Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: A review
Houseknecht, K. L., Cole, B. M., & Steele, P. J. (2002) · Domestic Animal Endocrinology · doi:10.1016/s0739-7240(01)00117-5 · Cited by 232
Tachibana, K., Yamasaki, D., Ishimoto, K., & Doi, T. (2008) · PPAR Research · doi:10.1155/2008/102737 · Cited by 223
“Consistent with this relatively high divergence among the subtype-specific ligand-binding domains, differential activation of PPARs by endogenous and exogenous compounds may account for the specific biological activity of the three PPAR subtypes [6, 7].”
BackgroundMultiple role of reactive oxygen species in the arterial wall
Napoli, C., de Nigris, F., & Palinski, W. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1198 · Cited by 239
“PPARg is a nuclear receptor that regulates fat cell development and glucose homeostasis, and is the molecular target of insulin-sensitizing agents used for the management of type 2 diabetes mellitus [Willson et al., 2000].”
BackgroundKrönke, G., Kadl, A., Ikonomu, E., Blüml, S., Fürnkranz, A., Sarembock, I. J., Bochkov, V. N., Exner, M., Binder, B. R., & Leitinger, N. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.142638 · Cited by 232
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Benzotriazole: An overview on its versatile biological behavior
Briguglio, I., Piras, S., Corona, P., Gavini, E., Nieddu, M., Boatto, G., & Carta, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.089 · Cited by 229
“lipid metabolism), cell proliferation, skin development and inflammatory process [220,221].”
BackgroundNagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233
The ROR nuclear orphan receptor subfamily: Critical regulators of multiple biological processes
Jetten, A. M., Kurebayashi, S., & Ueda, E. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)69048-2 · Cited by 232
Komar, C. M. (2005) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-3-41 · Cited by 219
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“PPARγ plays a role in regulating induced inflammatory responses, by inhibiting inflammatory cytokine production such as TNF, interleukin-1β (IL-1β), and IL-6, the production of nitric oxide and the expression of matrix metalloproteinase 9 and macrophage scavenger receptor 1 in many cell types, such as monocytes, macro…”
BackgroundPPARγ in human and mouse physiology
HEIKKINEN, S., AUWERX, J., & ARGMANN, C. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.03.006 · Cited by 221
“In addition, many synthetic compounds, most particularly the thiazolidinediones (TZDs), are potent PPARγ agonists (reviewed in [17,18]).”
BackgroundEhrenborg, E., & Krook, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001560 · Cited by 213
“Because the L-165041 is only a weak agonist of the murine PPAR , other more potent PPAR ligands were developed (Willson et al., 2000).”
BackgroundNakata, K., Tanaka, Y., Nakano, T., Adachi, T., Tanaka, H., Kaminuma, T., & Ishikawa, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.437 · Cited by 215
Target Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells
Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103779200 · Cited by 215
Self-citationFetoni, A. R., Paciello, F., Rolesi, R., Paludetti, G., & Troiani, D. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.02.022 · Cited by 201
Honda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210
“AST (IU/L) 2161 [11-34] 64618‡ [19-120] 4565‡ [20-101]”
InfluentialNadra, K., Anghel, S. I., Joye, E., Tan, N. S., Basu-Modak, S., Trono, D., Wahli, W., & Desvergne, B. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3266-3281.2006 · Cited by 198
“5 21 6 (29) 15 (71) 0 0 P 21 1820 626 (34) 1,165 (64) 29 (1.”
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
Torra, I. P., Chinetti, G., Duval, C., Fruchart, J.-C., & Staels, B. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00002 · Cited by 210
Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252790.70572.0c · Cited by 201
Self-citationBeneficial effects of PPAR-? ligands in ischemia?reperfusion injury, inflammation and shock
ABDELRAHMAN, M., SIVARAJAH, A., & THIEMERMANN, C. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.008 · Cited by 205
“The essential fatty acids arachidonic acid, gamolenic acid, docosahexanoic acid, and eicosapentaenoic acid, as well as modified oxidised lipids [9- and 13-hydroxyoctadecadienoic acid (9- and -HODE) and 12- and 15-hydroxyeicosatetraenoic acid (12- and 15-HETE)], bind to and activate PPAR-g [ 21 ].”
BackgroundInfluentialIde, T., Shimano, H., Yoshikawa, T., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Nakakuki, M., Yatoh, S., Iizuka, Y., Tomita, S., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0191 · Cited by 199
“PPARs are known to regulate expression of numerous genes involved in fatty acid metabolism and adipocyte differentiation (2, 3).”
BackgroundThe Small Molecule Harmine Is an Antidiabetic Cell-Type-Specific Regulator of PPARγ Expression
Waki, H., Park, K. W., Mitro, N., Pei, L., Damoiseaux, R., Wilpitz, D. C., Reue, K., Saez, E., & Tontonoz, P. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.010 · Cited by 202
Wagner, K.-D., & Wagner, N. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.001 · Cited by 189
Vitamin A Metabolism, Action, and Role in Skeletal Homeostasis
Conaway, H. H., Henning, P., & Lerner, U. H. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1071 · Cited by 189
Regulation of long-chain polyunsaturated fatty acid biosynthesis in teleost fish
Xie, D., Chen, C., Dong, Y., You, C., Wang, S., Monroig, Ó., Tocher, D. R., & Li, Y. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101095 · Cited by 192
Immune Mechanisms in Thyroid Eye Disease
Lehmann, G. M., Feldon, S. E., Smith, T. J., & Phipps, R. P. (2008) · Thyroid · doi:10.1089/thy.2007.0407 · Cited by 194
“It binds lipid ligands, dimerizes with retinoid-X receptor alpha (RXRa), translocates to the nucleus, and alters the transcription of genes containing peroxisome proliferator responsive elements (59).”
Regulation of Human Sebaceous Glands
Thiboutot, D. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.1523-1747.2004.t01-2-.x · Cited by 192
Recent advances in structure-based rational drug design
Gane, P. J., & Dean, P. M. (2000) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00105-6 · Cited by 192
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Luna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martínez, A., & Perez-Castillo, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414390200 · Cited by 190
INESTROSA, N., GODOY, J., QUINTANILLA, R., KOENIG, C., & BRONFMAN, M. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.09.032 · Cited by 187
Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Heymann, F., Trautwein, C., & Tacke, F. (2009) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152809789352230 · Cited by 189
Fission and proliferation of peroxisomes
Schrader, M., Bonekamp, N. A., & Islinger, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.014 · Cited by 189
“Concerning the species differences in peroxisome proliferation, the affinities of endogenous or exogenous ligands to PPARα were not found to be responsible as was shown by experiments with speciesspecific PPARαs and reporter constructs based on the rat PPAR response element [32–34].”
BackgroundKurtz, T. W., & Pravenec, M. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00003 · Cited by 182
Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M., & Sigmund, C. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000116303.71408.c2 · Cited by 184
Identification of a subtype selective human PPARα agonist through parallel-array synthesis
Brown, P. J., Stuart, L. W., Hurley, K. P., Lewis, M. C., Winegar, D. A., Wilson, J. G., Wilkison, W. O., Ittoop, O. R., & Willson, T. M. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00188-3 · Cited by 177
Self-citationNeuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies
Kohno, M., Link, J., Dennis, L. E., McCready, H., Huckans, M., Hoffman, W. F., & Loftis, J. M. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.01.007 · Cited by 170
“PPAR-γ activation has anti-inflammatory effects that involve inhibiting the expression of cytokines (IL-1β, IL-6, and TNF-α), the production of inducible nitric oxide, and the expression of matrix metalloproteinase 9 and macrophage scavenger receptor 1 on monocytes, macrophages, and epithelial cells (Daynes and Jones,…”
The Emerging Functions of UCP2 in Health, Disease, and Therapeutics
Mattiasson, G., & Sullivan, P. G. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1 · Cited by 177
Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives
Chapman, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00156-4 · Cited by 180
Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programme
Varley, C. L., Stahlschmidt, J., Lee, W.-C., Holder, J., Diggle, C., Selby, P. J., Trejdosiewicz, L. K., & Southgate, J. (2004) · Journal of Cell Science · doi:10.1242/jcs.01042 · Cited by 175
“However, our results suggest that TZ was more active than RZ at inducing uroplakin gene expression in NHU cells, whereas IC50 data from transactivation studies implies that RZ is Journal of Cell Science 117 (10) tenfold more potent than TZ (Willson et al., 2000).”
BackgroundResultLi, X., Ycaza, J., & Blumberg, B. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.03.012 · Cited by 177
The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor γ and Its Therapeutic Modulation
Gurnell, M., Savage, D. B., Chatterjee, V. K. K., & O’Rahilly, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030435 · Cited by 179
Wang, Y., Porter, W. W., Suh, N., Honda, T., Gribble, G. W., Leesnitzer, L. M., Plunket, K. D., Mangelsdorf, D. J., Blanchard, S. G., Willson, T. M., et al. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.10.0545 · Cited by 171
Self-citationPPARγ signaling exacerbates mammary gland tumor development
Saez, E., Rosenfeld, J., Livolsi, A., Olson, P., Lombardo, E., Nelson, M., Banayo, E., Cardiff, R. D., Izpisua-Belmonte, J. C., & Evans, R. M. (2004) · Genes & Development · doi:10.1101/gad.1167804 · Cited by 178
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Identification of Farnesoid X Receptor β as a Novel Mammalian Nuclear Receptor Sensing Lanosterol
Otte, K., Kranz, H., Kober, I., Thompson, P., Hoefer, M., Haubold, B., Remmel, B., Voss, H., Kaiser, C., Albers, M., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.864-872.2003 · Cited by 176
“Similar affinities are reported for the physiological ligands of other lipid receptors (14, 18, 34).”
BackgroundRegulation of food intake by oleoylethanolamide
Lo Verme, J., Gaetani, S., Fu, J., Oveisi, F., Burton, K., & Piomelli, D. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4494-0 · Cited by 169
Rival, Y., Benéteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J.-F., Junquéro, D., Colpaert, F. C., & Delhon, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01589-8 · Cited by 173
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 166
“is pan - (alpha, beta, gamma) PPAR balanced activator [54,55].”
BackgroundThiazolidine-2,4-diones: Progress towards multifarious applications
Jain, V. S., Vora, D. K., & Ramaa, C. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.01.029 · Cited by 165
Sottile, V., Seuwen, K., & Kneissel, M. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0224-8 · Cited by 178
“TZDs bind and activate the nuclear receptor PPARgamma, which exerts critical control over the adipocyte differentiation process [3–5].”
BackgroundSiddiqui, A. M., Cui, X., Wu, R., Dong, W., Zhou, M., Hu, M., Simms, H. H., & Wang, P. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000221921.71300.bf · Cited by 174
“First discovered in adipocytes with a role in differentiation and subsequently implicated in diabetes, PPAR- is now known to be expressed in monocyte/ macrophage lineage (36).”
BackgroundDi Marzio, D. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s993 · Cited by 169
Retinoic Acid Actions through Mammalian Nuclear Receptors
Huang, P., Chandra, V., & Rastinejad, F. (2014) · Chemical Reviews · doi:10.1021/cr400161b · Cited by 162
Tenenbaum, A., Motro, M., Fisman, E. Z., Schwammenthal, E., Adler, Y., Goldenberg, I., Leor, J., Boyko, V., Mandelzweig, L., & Behar, S. (2004) · Circulation · doi:10.1161/01.cir.0000126824.12785.b6 · Cited by 174
Derosa, G., Sahebkar, A., & Maffioli, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25804 · Cited by 165
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Camacho, I. E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., & De Strooper, B. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 168
The role of fibric acids in atherosclerosis
Fruchart, J.-C., Staels, B., & Duriez, P. (2001) · Current Atherosclerosis Reports · doi:10.1007/s11883-001-0015-x · Cited by 170
Fu, M., Zhang, J., Zhu, X., Myles, D. E., Willson, T. M., Liu, X., & Chen, Y. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105490200 · Cited by 170
Self-citationHiggins, L. S., & DePaoli, A. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449e · Cited by 166
On the Role of Liver X Receptors in Lipid Accumulation in Adipocytes
Juvet, L. K., Andresen, S. M., Schuster, G. U., Dalen, K. T., Tobin, K. A. R., Hollung, K., Haugen, F., Jacinto, S., Ulven, S. M., Bamberg, K., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2001-0210 · Cited by 168
Palombo, J. D., Ganguly, A., Bistrian, B. R., & Menard, M. P. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00796-0 · Cited by 168
Pineda Torra, I., Jamshidi, Y., Flavell, D. M., Fruchart, J.-C., & Staels, B. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.5.0833 · Cited by 164
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
Quinn, C. E., Hamilton, P. K., Lockhart, C. J., & McVeigh, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 166
“The combination of PPAR-a and -g effects could therefore offer superior treatment of insulin resistance and cardioprotection than the individual agonists (Willson et al., 2000; Chinetti et al., 2001).”
BackgroundPPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases
Lin, Y., Wang, Y., & Li, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074911 · Cited by 182
Landreth, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169
Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22756 · Cited by 160
Ramanan, S., Kooshki, M., Zhao, W., Hsu, F.-C., & Robbins, M. E. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.002 · Cited by 159
“PPARα, while classically known to be involved in fatty acid oxidation, has recently been demonstrated to be an important anti-inflammatory mediator [21].”
BackgroundDyslipidemia and cardiovascular risk: the importance of early prevention
Miller, M. J. (2009) · QJM · doi:10.1093/qjmed/hcp065 · Cited by 195
Ricote, M., Valledor, A. F., & Glass, C. K. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000103951.67680.b1 · Cited by 162
The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance
Plutzky, J. (2011) · Circulation Research · doi:10.1161/circresaha.110.226860 · Cited by 159
Multi-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 178
“In 2012 Imig and Hammock studied the effects of the selective PPARγ agonist Rosiglitazone (2) (Willson et al., 2000) in combination with t-AUCB (1) (Figure 2) in order to decrease renal injury in spontaneously hypertensive obese (SHROB) rats (Imig et al., 2012).”
BackgroundEffects of Fibrates on Serum Metabolic Parameters
Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000516 · Cited by 164
Physiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
Dello Russo, C., Gavrilyuk, V., Weinberg, G., Almeida, A., Bolanos, J. P., Palmer, J., Pelligrino, D., Galea, E., & Feinstein, D. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208132200 · Cited by 164
15-Lipoxygenase Metabolism of 2-Arachidonylglycerol
Kozak, K. R., Gupta, R. A., Moody, J. S., Ji, C., Boeglin, W. E., DuBois, R. N., Brash, A. R., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201084200 · Cited by 160
Minireview: Role Of Orphan Nuclear Receptors in Cancer and Potential as Drug Targets
Safe, S. H., Jin, U.-H., Hedrick, E., Reeder, A., & Lee, S. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1291 · Cited by 164
Guignabert, C., Alvira, C. M., Alastalo, T., Sawada, H., Hansmann, G., Zhao, M., Wang, L., El‐Bizri, N., & Rabinovitch, M. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00199.2009 · Cited by 158
“THE PEROXISOME PROLIFERATOR-ACTIVATED receptors (PPARs) belong to a family of three nuclear proteins [ , ( ), and ] that have tissue-specific overlapping functions as transcription factors (3, 6, 41, 43).”
BackgroundOxidative Stress and Transcriptional Regulation in Alzheimer Disease
Shi, Q., & Gibson, G. E. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815721c3 · Cited by 157
Maglich, J. M., Caravella, J. A., Lambert, M. H., Willson, T. M., Moore, J. T., & Ramamurthy, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg444 · Cited by 169
“Mammalian PPARs contain four highly conserved residues that make hydrogen bonds to the acid head-group of their fatty acid ligands (40).”
BackgroundProspects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)
Sporn, M. B., Suh, N., & Mangelsdorf, D. J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02100-1 · Cited by 159
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J., Devchand, P., Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 153
Kallwitz, E. R., McLachlan, A., & Cotler, S. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.22 · Cited by 150
Role of Lipotoxicity in Endothelial Dysfunction
Kim, J.-A., Montagnani, M., Chandrasekran, S., & Quon, M. J. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.012 · Cited by 144
Abraham, V. C., Towne, D. L., Waring, J. F., Warrior, U., & Burns, D. J. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108318428 · Cited by 153
Khan, S. A., & Heuvel, J. P. V. (2003) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(03)00098-6 · Cited by 180
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.